AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33300880 — intervention group
Group type: COMPARATOR
Intervention: Control side (contralateral side)
Number of subjects: 17
Study 33300880 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) treatment on the intervention side
Number of subjects: 17
Study 35337672 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and dietary intervention
Number of subjects: 24
Study 35337672 — intervention group
Group type: COMPARATOR
Intervention: Usual care with counseling sessions post-treatment
Number of subjects: 24
Study 33523004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling (moderate-intensity, 20-50 minutes, 3 times a week for 6 months)
Number of subjects: 96
Study 33523004 — intervention group
Group type: COMPARATOR
Intervention: Stretching (light-intensity)
Number of subjects: 96
Study 33523004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 96
Study 33523004 — intervention group
Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 96
Study 32878899 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid treatment
Number of subjects: 0
Study 32878899 — intervention group
Group type: EXPERIMENTAL
Intervention: Early administration of tranexamic acid
Number of subjects: 0
Study 32878899 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe TBI treatment with tranexamic acid
Number of subjects: 0
Study 34628421 — intervention group
Group type: EXPERIMENTAL
Intervention: Visco-circumferential-suture-trabeculotomy (VCST)
Number of subjects: 49
Study 34628421 — intervention group
Group type: COMPARATOR
Intervention: Rigid probe viscotrabeculotomy (VT)
Number of subjects: 49
Study 32895571 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab + axitinib
Number of subjects: 886
Study 32895571 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 886
Study 35576873 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium + Vitamin D (MagD; 360 mg magnesium glycinate + 1000 IU vitamin D 3 × daily)
Number of subjects: 95
Study 35576873 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium + Vitamin D (MagD)
Number of subjects: 95
Study 35576873 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D only (VitD; 1000 IU vitamin D 3 × daily)
Number of subjects: 95
Study 35576873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 32376505 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab therapy
Number of subjects: 484
Study 32376505 — intervention group
Group type: COMPARATOR
Intervention: External validation models
Number of subjects: 484
Study 35172779 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT combined with modified docetaxel chemotherapy (docetaxel 40 mg/m2 on the 1st day and 35 mg/m2 on the 8th day, repeated every 21 days)
Number of subjects: 128
Study 35172779 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT combined with modified docetaxel chemotherapy
Number of subjects: 128
Study 35172779 — intervention group
Group type: COMPARATOR
Intervention: ADT combined with standard docetaxel chemotherapy
Number of subjects: 128
Study 34173659 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelia Aspergillus galactomannan (GM) enzyme immunoassay (EIA)
Number of subjects: 471
Study 34173659 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungitell β‐d‐glucan (BDG) assay
Number of subjects: 471
Study 34173659 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of GM EIA and BDG assay
Number of subjects: 471
Study 34173659 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole prophylaxis
Number of subjects: 471
Study 34173659 — intervention group
Group type: COMPARATOR
Intervention: Caspofungin prophylaxis
Number of subjects: 471
Study 35013991 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-contingent group
Number of subjects: 0
Study 35013991 — intervention group
Group type: COMPARATOR
Intervention: Random group
Number of subjects: 0
Study 35486948 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized progesterone (MP) in combination with transdermal estradiol (t‐E2)
Number of subjects: 57
Study 35486948 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) in combination with transdermal estradiol (t‐E2)
Number of subjects: 57
Study 35486948 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MP and MPA
Number of subjects: 57
Study 35486948 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 57
Study 35040887 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor (ticagrelor or clopidogrel) plus therapeutic dose of heparin (n=293)
Number of subjects: 562
Study 35040887 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic dose of heparin only (usual care) (n=269)
Number of subjects: 562
Study 33745624 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary calcium intake (less than vs. more than median value)
Number of subjects: 466
Study 33745624 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary calcium intake (less than vs. equal or more than RDA)
Number of subjects: 466
Study 33745624 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary calcium intake (median)
Number of subjects: 466
Study 33745624 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary zinc intake (equal or more than RDA)
Number of subjects: 466
Study 33745624 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary zinc intake (more than median)
Number of subjects: 466
Study 33745624 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary iron intake (equal or more than RDA)
Number of subjects: 466
Study 33745624 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary iron intake
Number of subjects: 466
Study 34344399 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapropterin at 10 mg/kg/day (increased up to 20 mg/kg/day) plus Phe-restricted diet in the 'sapropterin extension' group (n = 26)
Number of subjects: 51
Study 34344399 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapropterin plus Phe-restricted diet in the 'sapropterin continuous' group (n = 25)
Number of subjects: 51
Study 32157182 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal stromal pocket irrigation with balanced salt solution
Number of subjects: 121
Study 32157182 — intervention group
Group type: COMPARATOR
Intervention: No irrigation (control group)
Number of subjects: 121
Study 34910297 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (THD)
Number of subjects: 160
Study 34910297 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 34660195 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxingshigan-Weijing Decoction (MWD) with routine supportive care
Number of subjects: 59
Study 34660195 — intervention group
Group type: COMPARATOR
Intervention: Routine supportive care alone
Number of subjects: 59
Study 33118624 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS)
Number of subjects: 68
Study 33118624 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 68
Study 32423937 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 160
Study 32423937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 34061234 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sacrocolpopexy/cervicopexy (LSC‐Cx)
Number of subjects: 120
Study 34061234 — intervention group
Group type: COMPARATOR
Intervention: Anterior vaginal mesh (AVM)
Number of subjects: 120
Study 33545954 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic therapy combined with acupuncture
Number of subjects: 0
Study 33545954 — intervention group
Group type: COMPARATOR
Intervention: Simple acupuncture
Number of subjects: 0
Study 36617611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal acupuncture
Number of subjects: 120
Study 36617611 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (budesonide nasal spray and loratadine)
Number of subjects: 120
Study 32919848 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Vancomycin Powder and Dilute Povidone-Iodine Lavage (VIP)
Number of subjects: 0
Study 32919848 — intervention group
Group type: COMPARATOR
Intervention: High-risk TKA patients
Number of subjects: 0
Study 33199418 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow oxygen with head side elevation
Number of subjects: 138
Study 33199418 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow oxygen with head side elevation
Number of subjects: 138
Study 33199418 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no oxygen provided)
Number of subjects: 138
Study 35732183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention providing appointment and referral opportunity to community therapy
Number of subjects: 0
Study 35732183 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 0
Study 35732183 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment groups (Intervention + TAU)
Number of subjects: 0
Study 35732183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention and TAU
Number of subjects: 0
Study 34506827 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided treatment with ticagrelor for carriers of CYP2C19 loss-of-function alleles and clopidogrel for noncarriers.
Number of subjects: 755
Study 34506827 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with clopidogrel.
Number of subjects: 755
Study 36289532 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 0
Study 36289532 — intervention group
Group type: COMPARATOR
Intervention: 7+3
Number of subjects: 0
Study 33449510 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM)
Number of subjects: 285
Study 33449510 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestion (HS)
Number of subjects: 285
Study 33449510 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral pain psychoeducation
Number of subjects: 285
Study 34081560 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate extended-release orally disintegrating tablets (MPH XR-ODT) 20 mg daily, adjusted weekly by 10-20 mg during a 4-week dose-optimization period.
Number of subjects: 0
Study 32615117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ripretinib
Number of subjects: 0
Study 32615117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36109354 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Methylene Blue (MB)
Number of subjects: 90
Study 36109354 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% Ropivacaine
Number of subjects: 90
Study 36109354 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Methylene Blue (MB) and 0.75% Ropivacaine mixture
Number of subjects: 90
Study 34795121 — intervention group
Group type: EXPERIMENTAL
Intervention: epidermal growth factor receptor‐tyrosine kinase inhibitors
Number of subjects: 0
Study 34795121 — intervention group
Group type: EXPERIMENTAL
Intervention: cytotoxic chemotherapeutic agents
Number of subjects: 0
Study 34795121 — intervention group
Group type: EXPERIMENTAL
Intervention: immune checkpoint inhibitors
Number of subjects: 0
Study 35499834 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured, 2-year, partially supervised, moderate-intensity physical activity and exercise intervention
Number of subjects: 1199
Study 35499834 — intervention group
Group type: COMPARATOR
Intervention: Health education control intervention
Number of subjects: 1199
Study 32316864 — intervention group
Group type: EXPERIMENTAL
Intervention: Amazake
Number of subjects: 17
Study 32316864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 36180923 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAM app-based program
Number of subjects: 0
Study 36180923 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33725939 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 0
Study 33725939 — intervention group
Group type: COMPARATOR
Intervention: Microsurgical clipping
Number of subjects: 0
Study 34075841 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of Ellagic Acid (100 mg) plus Annona Muricata (100 mg), daily for 6 months
Number of subjects: 162
Study 32771313 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning-based algorithm using U-Net architecture for SAT and VAT quantification
Number of subjects: 7
Study 32771313 — intervention group
Group type: COMPARATOR
Intervention: Manual segmentation of SAT and VAT
Number of subjects: 7
Study 32771313 — intervention group
Group type: COMPARATOR
Intervention: Automated segmentation of SAT and VAT
Number of subjects: 7
Study 33506965 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 long‐chain polyunsaturated fatty acid (n‐3 LCPUFA) supplementation during third trimester of pregnancy
Number of subjects: 736
Study 32612066 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (DAPA)
Number of subjects: 83
Study 32612066 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 83
Study 35301859 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg glibenclamide
Number of subjects: 22
Study 35301859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 34362409 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based stepwise diabetes prevention program with added financial incentives
Number of subjects: 846
Study 32475446 — intervention group
Group type: EXPERIMENTAL
Intervention: Star anise oil (SAO) supplementation at 400 mg/kg
Number of subjects: 512
Study 32475446 — intervention group
Group type: EXPERIMENTAL
Intervention: Star anise oil (SAO) supplementation at 200 mg/kg
Number of subjects: 512
Study 32475446 — intervention group
Group type: EXPERIMENTAL
Intervention: Star anise oil (SAO) supplementation at 600 mg/kg
Number of subjects: 512
Study 32475446 — intervention group
Group type: COMPARATOR
Intervention: Star anise oil (SAO) supplementation at 0 mg/kg (control)
Number of subjects: 512
Study 32475446 — intervention group
Group type: COMPARATOR
Intervention: E. coli challenge
Number of subjects: 512
Study 35421071 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoTrac ESD
Number of subjects: 150
Study 35421071 — intervention group
Group type: COMPARATOR
Intervention: Conventional ESD
Number of subjects: 150
Study 33372291 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (ACSs) - betamethasone or dexamethasone
Number of subjects: 982
Study 32819997 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention prior to vaccination in addition to standard care
Number of subjects: 100
Study 32819997 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study 32819997 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention
Number of subjects: 100
Study 35944021 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated reduced gravity (1, 0.76, 0.54, and 0.31 gravity)
Number of subjects: 12
Study 35944021 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking speed (0.4, 0.8, 1.2, and 1.6 m/s)
Number of subjects: 12
Study 35944021 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow walking (0.4 m/s)
Number of subjects: 12
Study 35944021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic muscle-tendon unit stiffness
Number of subjects: 12
Study 35944021 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking speed
Number of subjects: 12
Study 33065258 — intervention group
Group type: EXPERIMENTAL
Intervention: vNOTES hysterectomy
Number of subjects: 114
Study 36862239 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg dexamethasone daily
Number of subjects: 357
Study 36862239 — intervention group
Group type: COMPARATOR
Intervention: 6 mg dexamethasone daily
Number of subjects: 357
Study 33148620 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab (irinotecan 165 mg/m2, oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 3200 mg/m2)
Number of subjects: 349
Study 33148620 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX plus bevacizumab (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2 then 2400 mg/m2)
Number of subjects: 349
Study 33148620 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab
Number of subjects: 349
Study 33148620 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX plus bevacizumab
Number of subjects: 349
Study 36164744 — intervention group
Group type: EXPERIMENTAL
Intervention: Online clinical mentoring sessions (6 sessions)
Number of subjects: 24
Study 36164744 — intervention group
Group type: COMPARATOR
Intervention: Asynchronous online lectures (6 lectures)
Number of subjects: 24
Study 36164744 — intervention group
Group type: EXPERIMENTAL
Intervention: Online clinical mentoring
Number of subjects: 24
Study 33882970 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine combined with sufentanil and dezocine‐based PCIA (group D)
Number of subjects: 152
Study 33882970 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil and dezocine‐based PCIA (group C)
Number of subjects: 152
Study 33882970 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 152
Study 33313730 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile+Group LAMP
Number of subjects: 0
Study 33313730 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile LAMP
Number of subjects: 0
Study 33313730 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 34368934 — intervention group
Group type: EXPERIMENTAL
Intervention: Friendly Schools Friendly Families (FSFF) anti-bullying intervention
Number of subjects: 0
Study 33308359 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril and folic acid (10 mg enalapril and 0.8 mg folic acid daily)
Number of subjects: 8208
Study 33308359 — intervention group
Group type: COMPARATOR
Intervention: Enalapril only (10 mg daily)
Number of subjects: 8208
Study 33251687 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep injection technique targeting the supraperiosteal plane
Number of subjects: 14
Study 33251687 — intervention group
Group type: COMPARATOR
Intervention: Superficial injection technique in the superficial fatty layer
Number of subjects: 14
Study 33371123 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with conventional treatment (treatment A) for 6 weeks
Number of subjects: 40
Study 33371123 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone (treatment C) for 6 weeks
Number of subjects: 40
Study 33371123 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with conventional treatment (treatment A)
Number of subjects: 40
Study 33371123 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone (treatment C)
Number of subjects: 40
Study 34480570 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 days of complete bed rest with energy intake reduced to maintain energy balance and fat mass
Number of subjects: 20
Study 34480570 — intervention group
Group type: COMPARATOR
Intervention: Standardized culture conditions for adipose tissue
Number of subjects: 20
Study 32870801 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid learning method for system identification and optimal control using neural networks and reinforcement learning.
Number of subjects: 0
Study 33337706 — intervention group
Group type: EXPERIMENTAL
Intervention: G40% (40% of body mass)
Number of subjects: 60
Study 33337706 — intervention group
Group type: COMPARATOR
Intervention: G0% (0% of body mass)
Number of subjects: 60
Study 33337706 — intervention group
Group type: COMPARATOR
Intervention: G60% (60% of body mass)
Number of subjects: 60
Study 33337706 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 33337706 — intervention group
Group type: EXPERIMENTAL
Intervention: G80% (80% of body mass)
Number of subjects: 60
Study 35181234 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis
Number of subjects: 78
Study 35181234 — intervention group
Group type: COMPARATOR
Intervention: Control (no self-hypnosis)
Number of subjects: 78
Study 32424335 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 25
Study 32424335 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 25
Study 35365841 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine and/or azithromycin
Number of subjects: 53
Study 35365841 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonenrolled patients)
Number of subjects: 53
Study 33812221 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple sclerosis (MS)
Number of subjects: 27209
Study 34676916 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded implants (IL)
Number of subjects: 32
Study 34676916 — intervention group
Group type: COMPARATOR
Intervention: 3-month post-placement loaded implants (DL)
Number of subjects: 32
Study 34676916 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform switched implants
Number of subjects: 32
Study 34676916 — intervention group
Group type: COMPARATOR
Intervention: Platform matching implants
Number of subjects: 32
Study 33257485 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine for 6 months
Number of subjects: 3127
Study 33257485 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 3127
Study 33310202 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Educational Intervention of Altruism (IEIA) for 14 weeks
Number of subjects: 280
Study 33310202 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 280
Study 32519507 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation for 10 weeks
Number of subjects: 78
Study 32519507 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 78
Study 35142082 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (CT); 6 months, 3 sessions per week, including resistance training and aerobic exercise
Number of subjects: 40
Study 35142082 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (CT); 6 months
Number of subjects: 40
Study 33017510 — intervention group
Group type: COMPARATOR
Intervention: Olaparib monotherapy
Number of subjects: 0
Study 33017510 — intervention group
Group type: COMPARATOR
Intervention: Olaparib in combination with bevacizumab
Number of subjects: 0